M&A · Healthcare · Pharmaceutical Preparations
Amryt Pharma plc to acquire Chiasma, Inc
Announced May 5, 2021 · Closed Aug 5, 2021
Deal value$297MEV $273M
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationAll stock$5.13 per share
Transaction
- Acquirer
- Amryt Pharma plc (AMYT)
- Target
- Chiasma, Inc (CHMA)
- Buyer type
- Strategic
- Offer price per share
- $5.13
- Enterprise value
- $273M
- Status
- Closed Aug 5, 2021
Deal protections
- Break fee (target pays)
- $8.0M · 2.7%
- Reverse fee (buyer pays)
- $5.0M · 1.7%
- Go-shop
- No-shop
- Financing
- —
Advisors
- To the acquirer
- Moelis
- To the target
- Torreya Partners
Sector context · Healthcare
- Comparable deals
- 16 in the prior 24 months
- Premium
- Sector median 45.0%
- EV / Adj. EBITDA
- Sector median 19.3x
- Break fee
- 2.7% vs. 3.1% sector median
Timeline
- AnnouncedMay 5, 2021
- Proxy filedJul 2, 2021
- Definitive proxyJul 2, 2021
- Shareholder voteAug 3, 2021
- ClosedAug 5, 2021